Nanomedicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2023-08-11 ms3000001383690883 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学
经验分享：6月2日投稿
6月23送审
7月10返回审稿意见，两个审稿人都建议小修后接收
7月21修回
7月28编辑让调整参考文献格式
7月30返回
8月4正式接收

整体速度还是比较快的

31 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2023-01-26 懒懒懒

偏重的研究方向：纳米医学;纳米
经验分享：返修回去快两周了，坐等

34 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2023-01-26 懒懒懒

偏重的研究方向：纳米载体;纳米医学;纳米
经验分享：返修回去快两周了

41 0

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2021-08-30 ms2000002129869582

已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？

69 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2019-01-20 lily00

各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？

203 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2021-12-29 乌云背后的幸福线

讨论怎么写？

50 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2021-12-28 桑晒麦拉

引言和讨论之间有什么区别？

43 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2018-06-28 ms2983094698733738

非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！

130 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2021-05-12 pharmman

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：制剂 ;药化
经验分享：了解一下发文章

74 0

[GetPortalCommentsPageByObjectIdResponse(id=2152263, encodeId=0f502152263e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：纳米载体;肿瘤靶向治疗;纳米医学 经验分享：6月2日投稿 6月23送审 7月10返回审稿意见，两个审稿人都建议小修后接收 7月21修回 7月28编辑让调整参考文献格式 7月30返回 8月4正式接收 整体速度还是比较快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4345434091, createdName=ms3000001383690883, createdTime=Fri Aug 11 14:19:17 CST 2023, time=2023-08-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111570, encodeId=d92921115e0c9, content=偏重的研究方向：纳米医学;纳米 经验分享：返修回去快两周了，坐等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 22:45:06 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111543, encodeId=f1502111543c3, content=偏重的研究方向：纳米载体;纳米医学;纳米 经验分享：返修回去快两周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/8F72649175B0EACFE0AD971F02370A8D/100, createdBy=99511942430, createdName=懒懒懒, createdTime=Thu Jan 26 19:37:57 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012911, encodeId=de931012911c4, content=已投稿nanomedicine有3周了，目前状态仍是under consideration，ADM：Not Assigned，这是什么情况和流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba895588982, createdName=ms2000002129869582, createdTime=Mon Aug 30 16:26:08 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565785, encodeId=034a565e8557, content=各位大侠，已投稿nanomedicine有1个月了，目前状态仍是under consideration，分配了ADM，麻烦问问nanomedicine的审稿流程是怎样的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b11663641, createdName=lily00, createdTime=Sun Jan 20 10:10:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095307, encodeId=7d9c109530e32, content=讨论怎么写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095308, encodeId=bf2e1095308d8, content=引言和讨论之间有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=844506, encodeId=c8d184450609, content=非常nice的杂志，编辑友好，效率高，选的加速发表。2周后一审修回，中间申请了一次延期，大修后2天接收。突破5分，希望越办越好！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27a45414023, createdName=ms2983094698733738, createdTime=Thu Jun 28 10:56:54 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964918, encodeId=2c4f9649189c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：制剂 ;药化 经验分享：了解一下发文章 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab25499417, createdName=pharmman, createdTime=Wed May 12 15:13:41 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=573023, encodeId=8d8b5e3023eb, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：纳米纳米纳米纳米纳米纳米纳米纳米, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/images/uploads/crc/2017-08-03/5982ec1dce1241501752349.JPG, createdBy=d04d1743163, createdName=1561b61f93m, createdTime=Thu Jun 27 19:14:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]

2019-06-27 1561b61f93m

审稿速度:1.0 | 投稿命中率:95.0
经验分享：纳米纳米纳米纳米纳米纳米纳米纳米

184 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务